Top Page
Sumitomo Dainippon Pharma Co
(OTC:4506)
Sumitomo Dainippon Pharma Co (4506) vs. iShares MSCI Japan ETF (EWJ)
Sumitomo Dainippon Pharma Co Business Overview & Revenue Model
Sumitomo Dainippon Pharma Co Earnings Call Summary
Sumitomo Dainippon Pharma Co Financial Statement Overview
| Breakdown | |||||
| TTM | Mar 2025 | Mar 2024 | Mar 2023 | Mar 2022 | Mar 2021 |
|---|---|---|---|---|---|
| Income Statement | Total Revenue | ||||
| 520.48B | 398.83B | 314.56B | 555.54B | 560.03B | 515.95B | Gross Profit |
| 379.35B | 245.40B | 187.98B | 376.63B | 402.91B | 378.18B | EBIT |
| 89.31B | 14.93B | -354.19B | -76.98B | 60.23B | 71.22B | EBITDA |
| 109.76B | 57.58B | -281.07B | -3.50B | 124.36B | 103.11B | Net Income Common Stockholders |
| 67.03B | 23.63B | -314.97B | -74.51B | 56.41B | 56.22B |
| Balance Sheet | Cash, Cash Equivalents and Short-Term Investments | ||||
| 23.12B | 23.12B | 29.05B | 163.65B | 238.58B | 223.18B | Total Assets |
| 742.60B | 742.60B | 907.51B | 1.13T | 1.31T | 1.31T | Total Debt |
| 305.42B | 305.42B | 418.88B | 334.72B | 269.05B | 273.82B | Net Debt |
| 282.31B | 282.31B | 389.84B | 191.24B | 66.06B | 80.12B | Total Liabilities |
| 573.13B | 573.13B | 751.37B | 727.96B | 634.44B | 659.95B | Stockholders Equity |
| 169.48B | 169.48B | 156.06B | 406.75B | 607.89B | 580.57B |
| Cash Flow | Free Cash Flow | ||||
| 105.33B | 8.00B | -257.62B | -805.00M | 17.75B | 124.80B | Operating Cash Flow |
| 117.23B | 16.50B | -241.89B | 11.94B | 31.24B | 135.60B | Investing Cash Flow |
| 7.59B | 99.75B | 33.04B | 52.42B | -18.28B | 8.88B | Financing Cash Flow |
| -27.81B | -108.84B | 77.85B | -146.82B | -21.43B | -57.22B |
Sumitomo Dainippon Pharma Co Technical Analysis
Sumitomo Dainippon Pharma Co Peers Comparison
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
64 Neutral | $359.15B | 14.88 | 13.50% | ― | 26.79% | ― | |
54 Neutral | $5.38B | 3.40 | -45.06% | 3.28% | 16.75% | -0.02% | |
| $7.86B | 25.73 | 5.34% | 3.86% | ― | ― | ||
| $2.30B | 14.93 | 7.90% | 0.01% | ― | ― | ||
| $15.12B | 11.57 | 12.99% | 2.67% | ― | ― | ||
| $47.69B | 65.73 | 1.50% | 4.43% | ― | ― | ||
82 Outperform | ¥238.77B | 7.33 | 3.50% | 8.08% | 25.92% |
Sumitomo Dainippon Pharma Co Corporate Events
Sumitomo Pharma Co., Ltd. has announced a strategic restructuring of its Asian business through a simplified absorption-type company split. This involves transferring 60% of shares of a newly established subsidiary to Marubeni Global Pharma Corporation, with the option to transfer the remaining 40% in the future. This move is expected to enhance Sumitomo Pharma’s operational focus and market positioning in Asia, potentially impacting stakeholders by aligning with Marubeni’s resources and market reach.
The most recent analyst rating on (JP:4506) stock is a Hold with a Yen460.00 price target. To see the full list of analyst forecasts on Sumitomo Dainippon Pharma Co stock, see the JP:4506 Stock Forecast page.
Sumitomo Pharma has announced ‘Reboot 2027,’ a strategic plan for FY2025-FY2027, aiming to stabilize its revenue base and enhance its position as an R&D-driven pharmaceutical company. The plan includes financial targets such as expanding sales of key products and reducing debt, alongside initiatives to innovate in oncology and regenerative medicine. The company seeks to improve its value creation cycle and establish a distinctive global presence, with a focus on strategic growth and innovation.
The most recent analyst rating on (JP:4506) stock is a Hold with a Yen460.00 price target. To see the full list of analyst forecasts on Sumitomo Dainippon Pharma Co stock, see the JP:4506 Stock Forecast page.
Sumitomo Pharma Co., Ltd. announced the transfer of its Asian business to a new subsidiary, with 60% of shares being acquired by Marubeni Global Pharma Corporation. This transaction is expected to generate a gain of approximately 45 billion yen, impacting the company’s financial forecast for the fiscal year ending March 2026.
The most recent analyst rating on (JP:4506) stock is a Hold with a Yen460.00 price target. To see the full list of analyst forecasts on Sumitomo Dainippon Pharma Co stock, see the JP:4506 Stock Forecast page.
Sumitomo Pharma Co., Ltd. announced a proposal to amend its Articles of Incorporation to transition to a company with an Audit & Supervisory Committee, aiming to enhance corporate governance and decision-making processes. The amendments will include changes to the roles of directors and the establishment of new provisions to support strategic discussions and improve oversight.
The most recent analyst rating on (JP:4506) stock is a Hold with a Yen460.00 price target. To see the full list of analyst forecasts on Sumitomo Dainippon Pharma Co stock, see the JP:4506 Stock Forecast page.
Sumitomo Pharma Co., Ltd. announced its plan to transition to a company with an Audit and Supervisory Committee, pending approval at the upcoming Annual Shareholders’ Meeting. The Board of Directors has appointed candidates for executive and key personnel roles, with several directors and committee members being confirmed, subject to shareholder approval. This transition is expected to enhance the company’s governance structure, potentially impacting its operational oversight and strategic direction.
The most recent analyst rating on (JP:4506) stock is a Hold with a Yen460.00 price target. To see the full list of analyst forecasts on Sumitomo Dainippon Pharma Co stock, see the JP:4506 Stock Forecast page.
Sumitomo Pharma Co., Ltd. announced a reversal of allowance for doubtful accounts amounting to 46,556 million yen in its non-consolidated financial statements for the fiscal year ended March 31, 2025. This adjustment, recorded as extraordinary income, will not affect the company’s consolidated profit or loss as it will be eliminated in the consolidated financial statements.
Sumitomo Pharma has revised its financial forecasts for the fiscal year ending March 31, 2025, showing an increase in expected revenue and profits due to higher-than-anticipated sales in North America. Additionally, the company recorded significant gains from the transfer of equity interests in its regenerative medicine and cell therapy business, which positively impacts its financial results.
Sumitomo Pharma Co., Ltd. has announced an extension of reduced remuneration for its directors due to ongoing financial challenges and a lack of dividend distribution for the fiscal year ended March 31, 2025. This decision reflects the company’s efforts to navigate its current business difficulties and its commitment to financial recovery, impacting its executive compensation structure.
Sumitomo Pharma Co., Ltd. has announced a strategic move involving the transfer of its Asian business to a new subsidiary, with 60% of the shares to be acquired by Marubeni Global Pharma Corporation. This decision is part of Sumitomo Pharma’s efforts to strengthen its financial foundation and achieve sustainable growth by leveraging Marubeni’s global network, with the company set to receive significant financial consideration from the transaction.
Sumitomo Pharma Co., Ltd. has announced its decision to transition from a company with an Audit & Supervisory Board to one with an Audit & Supervisory Committee, pending approval at the upcoming shareholders’ meeting. This move is intended to strengthen the company’s governance by enhancing the supervisory function of its board, allowing for faster decision-making and improved strategic discussions, ultimately aiming to increase corporate value.
Sumitomo Pharma Co., Ltd. has announced the refinancing of its existing borrowings through a syndicated loan to stabilize its financial position after a breach of financial covenants. The refinancing involves a term loan and a commitment line totaling 233 billion yen, with minimal expected impact on the company’s financial results for the fiscal year ending March 2025.